biostudies-literatureConte MMISE: Nabuccothe Campania Regional Government Lotta alle Patologie Oncologiche, iCURECampania Regional Government “Lotta alle Patologie Oncologiche”, iCUREMUR (PRIN 2020)EU: BBMRI: CANSERV projectVALERE: Vanvitelli per la Ricerca Program: Adip-Care1960https://www.ebi.ac.uk/biostudies/studies/S-EPMC10093005biostudies-literatureUnknown15(7)A large body of clinical and experimental evidence indicates that colorectal cancer is one of the most common multifactorial diseases. Although some useful prognostic biomarkers for clinical therapy have already been identified, it is still difficult to characterize a therapeutic signature that is able to define the most appropriate treatment. Gene expression levels of the epigenetic regulator histone deacetylase 2 (<i>HDAC2</i>) are deregulated in colorectal cancer, and this deregulation is tightly associated with immune dysfunction. By interrogating bioinformatic databases, we identified patients who presented simultaneous alterations in <i>HDAC2</i>, class II major histocompatibility complex transactivator (<i>CIITA)</i>, and beta-2 microglobulin (<i>B2M</i>) genes based on mutation levCancersTargeting HDAC2-Mediated Immune Regulation to Overcome Therapeutic Resistance in Mutant Colorectal Cancer.PMC10093005ID263CUPB21c17000030007101058620CW39SJ1682PRIN 2020 CW39SJDi Mauro AAltucci LMontella LCapasso LDe Simone MConte MNebbioso AfalseTargeting HDAC2-Mediated Immune Regulation to Overcome Therapeutic Resistance in Mutant Colorectal Cancer.A large body of clinical and experimental evidence indicates that colorectal cancer is one of the most common multifactorial diseases. Although some useful prognostic biomarkers for clinical therapy have already been identified, it is still difficult to characterize a therapeutic signature that is able to define the most appropriate treatment. Gene expression levels of the epigenetic regulator histone deacetylase 2 (<i>HDAC2</i>) are deregulated in colorectal cancer, and this deregulation is tightly associated with immune dysfunction. By interrogating bioinformatic databases, we identified patients who presented simultaneous alterations in <i>HDAC2</i>, class II major histocompatibility complex transactivator (<i>CIITA)</i>, and beta-2 microglobulin (<i>B2M</i>) genes based on mutation lev2023-01-01T00:00:00Z2023 Mar2026-04-08T12:35:51.482Z2025-04-05T19:42:21.806ZS-EPMC100930053704662010.3390/cancers15071960